Related Experiment Videos
[Niemann-Pick disease types A and B]
1Department of Neurobiology, Tottori University Faculty of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 1, 1995
Summary
Niemann-Pick disease types A and B stem from mutations in acid sphingomyelinase. Type A involves no enzyme activity, while type B has residual activity, impacting neuronal function through altered signaling pathways.
Area of Science:
- Biochemistry
- Genetics
- Neuroscience
Context:
- Niemann-Pick disease (NPD) types A and B are lysosomal storage disorders.
- Genetic mutations leading to acid sphingomyelinase (ASM) deficiency are the known cause.
- Type A is characterized by complete loss of ASM activity, while Type B exhibits residual activity.
Purpose:
- To elucidate the molecular basis and pathogenesis of Niemann-Pick disease types A and B.
- To investigate the role of ceramide and lysosphingolipids in neuronal dysfunction in NPD Type A.
- To establish and utilize a mouse model for studying NPD and potential gene therapies.
Summary:
- Mutations causing complete acid sphingomyelinase deficiency define Niemann-Pick disease Type A, whereas those causing residual activity define Type B.
- Acid sphingomyelinase-deficient mice mimic Type A human disease, serving as a model for somatic gene therapy.
- Neuronal cell dysfunction in Type A may involve abnormal phospholipid signaling, with ceramide and accumulating lysosphingolipids like sphingosylphocholine playing potential roles.
Impact:
- Provides a foundation for understanding the molecular mechanisms underlying Niemann-Pick disease types A and B.
- Highlights the potential of acid sphingomyelinase-deficient mice as a valuable model for therapeutic development, including somatic gene therapy.
- Suggests novel therapeutic targets by implicating ceramide and lysosphingolipid metabolism in the pathogenesis of neuronal dysfunction in Niemann-Pick disease Type A.